The TrumpRx Ledger Doesn't Balance

When President Trump announced the TrumpRx pricing framework in April, flanked by executives from 17 pharmaceutical companies representing 80% of the branded drug market, the terms of the grand bargain were laid out plainly. Drugmakers would cut list prices — in some cases by up to 70% — provide certain drugs free to Medicaid, and commit to building out American manufacturing capacity. Commerce Secretary Howard Lutnick put a number on the manufacturing side: $448 billion in domestic investment. In exchange, the companies would receive three-year exemptions from the 10% tariff on branded pharmaceuticals and, just as important, a single predictable pricing framework to replace the patchwork of pressures they had been navigating. ^[1][2] Trump made the promise explicit.

With this announcement, 17 of the world’s largest pharmaceutical companies, representing 80 percent of the branded drug market, have now agreed to sell their drugs to American patients at the lowest prices anywhere in the world. — Donald Trump

Lutnick tied the manufacturing commitment to the pricing relief.

That means $448 billion of drug manufacturing is coming to America. — Howard Lutnick

Months in, the ledger does not balance on either side. Start with the consumer column. In April, Senator Bernie Sanders released a report examining what TrumpRx had actually delivered for patients. The findings were stark: 15 of the 16 participating drugmakers had raised prices on 337 drugs since January 2025. The platform, Sanders concluded, failed to deliver. ^[3]

Unfortunately, despite President Trump’s rhetoric, prescription drug prices in America have only gone up, not down, since he was elected. — Bernie Sanders

Senator Elizabeth Warren went further when the administration expanded the platform in May, describing it as something closer to a reverse transfer. ^[4]

conduit for Big Pharma to steer consumers to expensive brand-name drugs when cheaper generics are available. — Elizabeth Warren

The consumer column, in other words, showed costs without commensurate benefit — drugmakers had made the concessions, but the savings had not materialized. The other side of the ledger was supposed to deliver pricing stability — a single framework pharma could plan around. That column collapsed in May, when the Supreme Court declined to hear challenges to the Inflation Reduction Act's Medicare drug price negotiation program. The court's refusal left intact a second, entirely independent pricing channel: Medicare can now negotiate prices directly on selected drugs, using what Bristol Myers Squibb described in its legal challenge as the threat of staggering tax penalties to compel access to their most valuable products at steeply discounted prices. ^[5] BMS had argued the program involved no real negotiation at all.

The program involves no genuine negotiations — which, after all, can sometimes fail. — Bristol Myers Squibb

The court was unmoved. The IRA channel survived intact, meaning the pricing stability pharma had traded concessions for — a single, predictable regime — never arrived. Instead, drugmakers now face two independent pricing pressures, each with its own logic and neither with a ceiling. And the regime itself keeps tightening. When TrumpRx launched, it covered roughly 40 medications. By June, the catalog had expanded to more than 800 drugs, with some brand-name discounts exceeding 80%. ^[6] The framework was not settling into a stable equilibrium. It was ratcheting. Each expansion widened the pool of drugs subject to price caps, and each new entrant normalized the manufacturing-for-tariff-relief trade as the cost of doing business in the American market. Johnson & Johnson listed four medications in April and pledged $55 billion for US facilities. ^[7] AstraZeneca, the first non-US drugmaker to sign a TrumpRx deal, committed $50 billion to US manufacturing and R&D by 2030. ^[8] This ratchet is landing on an industry already hollowed out by the 2027-2028 patent cliff. BMS's legacy portfolio has fallen from $25.7 billion in 2024 to $21.8 billion in 2025, with a further 12% to 16% drop projected as exclusivity losses continue. European patent expirations alone could strip another $1.5 billion to $2 billion in 2027. ^[9] Pfizer, facing its own wave of expirations — Ibrance in 2027, Eliquis and Vyndaqel in 2028 — has seen its stock fall 55% from its 2021 peak. ^[10][11] Merck is staring down the 2028 expiration of Keytruda, the cancer immunotherapy that has become one of the best-selling drugs in history. ^[12] The response has been a wave of acquisitions, each larger than the last. Pfizer bought Seagen for $43 billion and Metsera for $10 billion. Merck acquired Verona Pharma for $10 billion. ^[13] BMS moved from a $1.5 billion deal for Orbital Therapeutics in April to a $15.2 billion licensing agreement with China's Hengrui Pharmaceuticals in May — the largest US-China pharma partnership on record — covering 13 preclinical drug programs. ^[9][14] The deals escalate in size as the pressure does not let up, culminating in the potential $400 billion AstraZeneca-BMS merger now under discussion. ^[15] The asymmetry between the two parties is instructive. AstraZeneca, the likely acquirer, is thriving — revenue up 12%, profit up 77%, stock at an all-time high, targeting $80 billion in annual revenue by 2030. ^[16][8] It has treated the TrumpRx framework as a manageable cost of market access rather than an existential threat. BMS, by contrast, is down 35% from its 2022 peak, carrying over $47 billion in debt, and buying pipeline from every available source — AI drug discovery partnerships with Nvidia, Chinese licensing deals, and now, potentially, a merger that would effectively cede its independence. ^[10][17][15] But even AstraZeneca is not immune to the logic of the ratchet. In July, the company lost £20 billion in market value overnight when its Wainua heart drug trial failed, wiping out an estimated $2 billion to $6 billion in projected peak sales. ^[18] The episode was a reminder that in an environment where regulatory costs compound in one direction and pipeline risk in the other, no balance sheet is deep enough to guarantee safety. Pipeline depth is the only real moat, and the companies that lack it are running out of time to buy it. The TrumpRx framework was sold as a grand bargain that would deliver lower prices for consumers and a stable, predictable market for drugmakers. What has emerged instead is a ratchet with no release mechanism — costs compounding in both directions at once, and the consolidation that the promised stability was supposed to make unnecessary accelerating with each turn.